Literature DB >> 32709960

Brolucizumab-early real-world experience: BREW study.

Ashish Sharma1, Nilesh Kumar2, Nikulaa Parachuri2, Srinivas R Sadda3, Giulia Corradetti3, Jeffrey Heier4, Adam T Chin4,5, David Boyer6, Pouya Dayani6, Sruthi Arepalli7, Peter Kaiser7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32709960      PMCID： PMC8115627          DOI： 10.1038/s41433-020-1111-x

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  13 in total

1.  First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.

Authors:  Alaa Din Abdin; Wissam Aljundi; Khalil El Jawhari; Shady Suffo; Isabel Weinstein; Berthold Seitz
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

2.  Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study.

Authors:  Debdulal Chakraborty; Aniruddha Maiti; Jay U Sheth; Subhendu Boral; Soumen Mondal; Krishnendu Nandi; Tushar Sinha; Arnab Das
Journal:  Clin Ophthalmol       Date:  2021-09-07

Review 3.  Side Effects of Brolucizumab.

Authors:  Tahmineh Motevasseli; Saeed Mohammadi; Fatemeh Abdi; William R Freeman
Journal:  J Ophthalmic Vis Res       Date:  2021-10-25

4.  Anatomical and functional responses to single brolucizumab injection in neovascular age-related macular degeneration patients not responding to antiangiogenics: a case series.

Authors:  Silvio Zuccarini; Fabrizio Puce; Alessandro Crisà
Journal:  Drug Target Insights       Date:  2022-03-24

5.  Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration.

Authors:  Nadia Zakaria; Nicolas Guerard; Andres Emanuelli; Pravin Dugel; Jen Watts; Melissa Liew; Margarita Gekkieva; Markus Hinder
Journal:  Pharmacol Res Perspect       Date:  2022-04

6.  Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting.

Authors:  Anne Rübsam; Saskia Rau; Daniel Pilger; Oliver Zeitz; Antonia M Joussen
Journal:  J Ophthalmol       Date:  2022-03-25       Impact factor: 1.909

7.  Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD.

Authors:  Ramin Khoramnia; Marta S Figueroa; Lars-Olof Hattenbach; Carlos E Pavesio; Majid Anderesi; Robert Schmouder; Yu Chen; Marc D de Smet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-12-21       Impact factor: 3.535

8.  Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy.

Authors:  Young-Joon Jeon; Jae-Hui Kim; Jong-Woo Kim; Chul-Gu Kim
Journal:  J Clin Med       Date:  2021-12-08       Impact factor: 4.241

9.  [Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab].

Authors:  Martin Dominik Leclaire; Jost Lauermann; Florian Alten; Nicole Eter
Journal:  Ophthalmologe       Date:  2021-02-24       Impact factor: 1.059

10.  Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.

Authors:  Sarah Thiele; Frank G Holz; Louisa Maria Bulirsch; Marlene Saßmannshausen; Jennifer Nadal; Raffael Liegl
Journal:  Br J Ophthalmol       Date:  2021-04-12       Impact factor: 5.908
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.